Claritev (CTEV) Status update summary
Event summary combining transcript, slides, and related documents.
Status update summary
6 Mar, 2026Business performance and growth outlook
Achieved 6.7% growth in Q4 and record bookings in 2025, forecasting strong double-digit bookings growth for the year.
Secured 10 new client logos in Q4, with pipeline up 167%, indicating robust future prospects.
ACV reached $67 million last year, with 70% from upsell/cross-sell and 30% from new clients; bookings typically convert to revenue in 2–4 quarters.
Diversified client base, reducing reliance on top five clients by 12%-15%.
Focused on organic growth and deleveraging, with clear priorities and consistent execution.
AI strategy and competitive positioning
Seven years into AI integration, leveraging proprietary data, workflow, and client trust as key differentiators.
AI-driven ProPricer engine delivered $20 million incremental revenue on flat claim volume.
Competitive moat built on embedded workflow, 1.4 million provider contracts, and deep client relationships.
AI models enhance negotiation, provider behavior prediction, and regulatory compliance.
Continual vigilance for AI-driven disruption, with plans to discuss further at Investor Day.
Capital allocation and transformation investments
Capital spend for 2026 guided at $160–$170 million, consistent with 2025, focused on tech modernization.
CapEx as a percentage of revenue at 15%-16%, expected to decline to 10% as transformation winds down by 2028.
Shift from CapEx to OpEx due to cloud migration, with no net cash flow impact.
M&A remains a disciplined priority, with recent acquisition of OPCG to enhance advisory services.
Primary focus remains on tech investment and deleveraging, with M&A and organic growth balanced.
Latest events from Claritev
- Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEV
Q4 202523 Feb 2026 - Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEV
Q2 20242 Feb 2026 - Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEV
Q3 202416 Jan 2026 - Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - 2024 revenue declined 3.2% and net loss spiked on impairment as transformation accelerates.CTEV
Q4 202423 Dec 2025 - Healthcare cost management firm files to offer up to $400M in securities for growth and operations.CTEV
Registration Filing16 Dec 2025 - Q3 2025 delivered 6.7% revenue growth, higher margins, and raised guidance on strong renewals.CTEV
Q3 202516 Dec 2025 - Renewed top clients, expanded pipeline, and strong growth in analytics drive positive outlook.CTEV
Piper Sandler 37th Annual Healthcare Conference4 Dec 2025 - Six new market segments and Oracle partnership drive growth and international expansion.CTEV
BofA Securities Leveraged Finance Conference 20253 Dec 2025